


## Insulin Toujeo® SoloStar® DoubleStar® Product Information Sheet & Good Practice Guide



### Insulin Toujeo® -Key Points

**High strength** basal Insulin product  
**Not bioequivalent** to glargine or other insulins  
**Units are exclusive** to the potency of Toujeo®  
**Dose adjustment** is needed **if switching** patients to or from Toujeo®

This information sheet has been produced to summarise key information about insulin Toujeo for those providing care for a patients on this insulin.

It is not specifically intended for diabetes specialists who are responsible for initiation and switching to/from insulin Toujeo®. Specialists are advised to refer to the SPC and local protocols for further information.

### Insulin Toujeo® Product Information (Requires **SPECIALIST INITIATION** i.e. Amber)

- Insulin Toujeo® contains **Insulin glargine 300 units/ml** in a pre-filled pen
- It is a **HIGH-STRENGTH Insulin Glargine product**
- It is a **basal insulin for ONCE DAILY use** (via subcutaneous injection)
- The potency of Toujeo® is stated in units. **These UNITS are EXCLUSIVE to Toujeo®** and are not the same as international units (IU) or the units used to express the potency of other insulin analogues
- Toujeo® is **NOT BIOEQUIVALENT** to Lantus or other basal insulins and **DOSE ADJUSTMENT** is needed when people are **SWITCHED to and from Toujeo®**
- Patients should only be switched to or from Toujeo® or initiated on treatment by a specialist in the care of diabetes. **Specialists are advised to refer to the SPC and local protocols for further information around initiation or switching.**
- It is metabolised in the same way as other insulin glargine products, but because of **DIFFERENCES in FORMULATION** it has a 'Flatter' and more prolonged insulin concentration (and glucose lowering activity) compared to alternative glargine products
- **ALWAYS PRESCRIBE BY BRAND NAME and INCLUDE the CONCENTRATION of INSULIN** i.e. (Toujeo® SoloStar® 300 units/ml or Toujeo® DoubleStar® 300 units/ml)
- Patients should be given a patient information booklet and an Insulin Passport to help provide accurate identification of their current insulin products and provide essential information across healthcare sectors.

